atorvastatin has been researched along with Bisphosphonate Osteonecrosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alves, K; Alves, NM; Brito, GAC; de Sousa, VC; Girão, V; Goes, P; Leitão, R; Lopes, AP; Martins, CS; Sousa, FRN; Vasconcelos, RF; Viana, D | 1 |
| Pazianas, M | 1 |
| Glick, A; Johnson, C; Sista, V | 1 |
3 other study(ies) available for atorvastatin and Bisphosphonate Osteonecrosis
| Article | Year |
|---|---|
Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats.
Topics: Animals; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Jaw; Osteonecrosis; Rats; Zoledronic Acid | 2022 |
Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats.
Topics: Animals; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Jaw; Osteonecrosis; Rats; Zoledronic Acid | 2022 |
Oral Manifestations of Commonly Prescribed Drugs.
Topics: Albuterol; Amlodipine; Anticonvulsants; Antihypertensive Agents; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bronchodilator Agents; Deprescriptions; Drug Hypersensitivity; Fluorides; Gingival Overgrowth; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Hypoglycemic Agents; Lisinopril; Losartan; Metformin; Metoprolol; Mouth Diseases; Omeprazole; Oral Hygiene; Proton Pump Inhibitors; Simvastatin; Thyroxine; Toothpastes; Xerostomia | 2020 |